LeadtoTreat

LeadtoTreat aims at developing a platform for future treatment of multidrug-resistant microbial infections, enabling targeted delivery of novel lead compounds with low drugability, as well as synergistic combinations of antibiotics and potentiators in a nanoformulation.

48 months
Duration
(Mar22–Feb26)
2,7 Mio €
Funding
3
Partners

Vision

The long-term vision of LeadtoTreat is to contribute to a radical shift in the treatment approach for antibiotic-resistant bacteria, by developing strain selective, targeted nanoformulations containing synergistic combinations of antibiotics and potentiators, leading to a platform and process that can rapidly increase the number of antibiotic treatments available.

Challenges

LeadtoTreat will address two major challenges in the treatment and eradication of microbial infections:

Resistance of many bacteria to
primary antibiotic treatments and
to drugs of last resort.
Poor solubility, protein adsorption
or unfavourable biodistribution of
promising novel lead compounds.

Objectives

  • Identify synergistic antibiotic combinations and potentiator/antibiotic combinations.
  • Develop novel targeting moieties for MRSA infection and inflammation based on nanobodies and short peptides.
  • Develop polyphosphazene polymer-based nanoformulations, loaded with selected antibiotics and potentiators.
  • Prove safety and efficacy in vitro and in vivo against MRSA

Approach

A toolbox of novel targeting nanoformulations containing antibiotics and/or potentiators enables selection, rapid adjustment and assembling in a modular approach to meet the challenges presented by novel bacterial mutations or strains, as they appear in the clinics. MRSA will be used as a first clinical indication.

The complementary expertise of the partners spans the entire value chain from drug screening to safety and efficacy testing.

Consortium

 logo
 logo
 logo

Contact

Geir Klingenberg photo
Geir Klingenberg
Project Coordinator